Trump signs order to speed review of psychedelics including ibogaine

President Trump signed an executive order directing faster federal review of certain psychedelics, including ibogaine, and the FDA plans to issue national priority vouchers and take steps to enable U.S. ibogaine trials.

President Donald Trump signed an executive order directing his administration to accelerate federal reviews of certain psychedelic drugs, including ibogaine. The signing took place at the White House with top health officials and outside advocates present. The administration says the move is intended to speed research and clinical trials on drugs regulators have called potential breakthroughs. Ibogaine remains in the federal government's most restrictive category and is known to carry safety risks. Key details: - The executive order directs faster review of certain psychedelics and specifically names ibogaine among those drugs. - The Food and Drug Administration plans to issue national priority vouchers for three psychedelics next week, which the FDA commissioner said can allow faster approvals if drugs align with national priorities. - The FDA is taking steps to clear the way for the first-ever human trials of ibogaine in the United States. - Ibogaine is currently classified as a Schedule I drug and has documented cardiovascular risks; medical literature cited by advocacy groups links it to more than 30 deaths. - Veterans groups, some conservative lawmakers, and advocates have supported access to ibogaine for conditions such as PTSD and opioid addiction, and some veterans have reported benefits after treatment abroad. - A recent law in Texas provided $50 million for ibogaine research at the state level, and some advocates said the federal action could encourage similar state programs. Summary: The executive order is intended to speed federal review and research on certain psychedelics and will be followed by FDA actions that include priority vouchers and procedural steps toward U.S. ibogaine trials. Officials and advocates say the move may increase federally acknowledged research and could influence state-level programs; the immediate clinical and regulatory impacts will follow ongoing FDA and research processes.